Chembio Diagnostics Inc (CEMI) was Reiterated by The Benchmark Company to “Speculative Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 8 from a previous price target of $6 . The Benchmark Company advised their investors in a research report released on Apr 18, 2016.
Chembio Diagnostics Inc opened for trading at $6.65 and hit $7.06 on the upside on Friday, eventually ending the session at $6.9, with a gain of 2.07% or 0.14 points. The heightened volatility saw the trading volume jump to 1,43,990 shares. Company has a market cap of $66 M.
In a different news, on May 29, 2015, Javan Esfandiari (Chief Science/Technology Offic) sold 20,000 shares at $4.50 per share price.
Chembio Diagnostics Inc. (Chembio) and its wholly owned subsidiary Chembio Diagnostic Systems Inc. develop manufacture market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s main products presently commercially available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples and are manufactured in a standard cassette format a dipstick format and a barrel format. Its Dual Path Platform (DPP) HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples as well as in all blood matrices. Additionally Chembio’s product pipeline includes a multiplex test that detects P24 HIV antigen as well as HIV 1/2 antibodies and a rapid test for the detection of Hepatitis-C antibodies.